TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Telomir Pharmaceuticals, Inc. ( (TELO) ) is now available.
Telomir Pharmaceuticals has reported new preclinical data demonstrating that its drug, Telomir-1, effectively inhibits DNA hypermethylation of the CDKN2A gene in aggressive human prostate cancer cells, outperforming Rapamycin and chemotherapy. These findings, which also include Telomir-1’s impact on the STAT1 gene, suggest its potential as a pioneering treatment targeting multiple tumor suppressor pathways, with ongoing studies exploring its application in various aggressive cancers.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies for cancer treatment. The company is actively engaged in creating first-in-class broad-spectrum DNA methylation reset therapies, with a particular emphasis on aggressive cancers.
Average Trading Volume: 4,527,062
Technical Sentiment Signal: Sell
Current Market Cap: $40.03M
See more insights into TELO stock on TipRanks’ Stock Analysis page.